Stifel Nicolaus initiated coverage on Precigen with a new price target
$PGEN
Biotechnology: Pharmaceutical Preparations
Health Care
Stifel Nicolaus initiated coverage of Precigen with a rating of Buy and set a new price target of $13.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/22/2024 | Neutral → Underweight | JP Morgan | |
| 5/23/2023 | Neutral | JP Morgan | |
| 11/18/2022 | $7.00 | Overweight | Cantor Fitzgerald |
10-Q - PRECIGEN, INC. (0001356090) (Filer)
8-K - PRECIGEN, INC. (0001356090) (Filer)
8-K - PRECIGEN, INC. (0001356090) (Filer)
GERMANTOWN, Md., Aug. 9, 2024 /PRNewswire/ -- Precigen, Inc. (NASDAQ:PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced the Company will release second quarter and first half 2024 financial results and provide business updates on Wednesday, August 14, 2024. The Company will host a conference call that day at 4:30 PM ET to discuss financial results and provide a general business update. The conference call may be accessed by dialing 1-800-836-8184 (North America) or 1-646-357
– Pivotal Phase 2 study data of PRGN-2012 for the treatment of patients with recurrent respiratory papillomatosis to be presented at the 2024 ASCO Annual Meeting as a late-breaking oral presentation on June 3rd – – Company to host a conference call on June 3rd following the PRGN-2012 ASCO presentation to discuss in detail the pivotal study results and provide business updates – – PRGN-2012 rolling BLA submission, under an accelerated approval pathway, is anticipated in the second half of 2024; commercial readiness activities underway for a potential launch in 2025 – – Two trial-in-progress presentations for PRGN-2009 in combination with pembrolizumab for the treatment of recurrent/m
GERMANTOWN, Md., May 8, 2024 /PRNewswire/ -- Precigen, Inc. (NASDAQ:PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced the Company will report first quarter 2024 financial results after the market close on Tuesday, May 14, 2024. No conference call is planned. The Company will host a conference call on Monday, June 3, 2024 to discuss in detail the pivotal Phase 2 study data of PRGN-2012 for the treatment of recurrent respiratory papillomatosis (RRP) presented at the 2024 Amer
– Company strengthens focus on building and optimizing commercial readiness and pre-launch activities for PRGN-2012 in recurrent respiratory papillomatosis – GERMANTOWN, Md., July 23, 2024 /PRNewswire/ -- Precigen, Inc. (NASDAQ:PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced the appointment of Phil Tennant as the Company's chief commercial officer. Mr. Tennant will be responsible for commercial strategy and execution across US and global markets. His initial focus will be on driving commercial readiness activities for the potential launch of the first- and best-in-class PRGN-2012 Aden
BERKELEY, Calif., April 24, 2024 /PRNewswire/ -- Actym Therapeutics, pioneering a new drug modality to treat solid tumors, announced today the appointment of Thomas Smart as Chief Executive Officer. With 25 years of experience in senior management and executive roles as well as Board of Directors positions across the biopharmaceutical industry, Mr. Smart brings a significant track record in leading organizations through value-building transitions. His breadth of expertise will be highly beneficial to Actym as it prepares to enter clinical evaluation of its lead candidate, ACTM-838, later this year.
– Inaugural multi-stakeholder event on June 11th (6/11) will raise awareness and bring together individuals living with RRP, caregivers, clinicians, and government officials – – RRP is a rare, HPV-driven disease with no FDA-approved therapeutic – GERMANTOWN, Md., March 28, 2024 /PRNewswire/ -- Precigen, Inc. (NASDAQ:PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced that the Company has teamed up with the Recurrent Respiratory Papillomatosis Foundation (RRPF) to launch the first RRP Awareness Day™ on June 11, 2024, a multi-stakeholder event to raise awareness about recurrent respirator
– Completed pre-BLA meeting with FDA with full alignment on content of BLA, including CMC module, and path for fourth quarter 2024 rolling BLA submission for PRGN-2012† in RRP under accelerated approval pathway – – Commercial and manufacturing readiness campaign underway for PRGN-2012 in anticipation of a potential 2025 launch – – Confirmatory clinical trial for PRGN-2012 in RRP was initiated in accordance with guidance from FDA to initiate prior to submission of the BLA; continuing enrollment – – Preparing for end of Phase 1b meeting with FDA in early 2025 for PRGN-3006 in AML – – Presented preclinical data at SITC 2024 for PRGN-3008, a next generation UltraCAR-T targeting CD19 sh
GERMANTOWN, Md., Nov. 12, 2024 /PRNewswire/ -- Precigen, Inc. (NASDAQ:PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced Helen Sabzevari, PhD, President and CEO of Precigen, will participate in a fireside chat on Tuesday, November 19, 2024 from 10:55 to 11:25 AM ET at the Stifel 2024 Healthcare Conference taking place November 18 to 19, 2024 in New York. Event details can be found on Precigen's website in the Events & Presentations section at investors.precigen.com/events-pr
GERMANTOWN, Md., Sept. 16, 2024 /PRNewswire/ -- Precigen, Inc. (NASDAQ:PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced that Helen Sabzevari, PhD, President and CEO of Precigen, will participate in a fireside chat on Wednesday, September 18, 2024 from 9:45 to 10:15 AM ET at the 2024 Cantor Global Healthcare Conference taking place September 17 to 19, 2024 in New York. Participants may view details for the event through Precigen's website in the Events & Presentations secti
JP Morgan downgraded Precigen from Neutral to Underweight
JP Morgan initiated coverage of Precigen with a rating of Neutral
Cantor Fitzgerald initiated coverage of Precigen with a rating of Overweight and set a new price target of $7.00
4 - PRECIGEN, INC. (0001356090) (Issuer)
4 - PRECIGEN, INC. (0001356090) (Issuer)
4 - PRECIGEN, INC. (0001356090) (Issuer)
SC 13D/A - PRECIGEN, INC. (0001356090) (Subject)
SC 13D/A - PRECIGEN, INC. (0001356090) (Subject)
SC 13G/A - PRECIGEN, INC. (0001356090) (Subject)
4 - PRECIGEN, INC. (0001356090) (Issuer)
4 - PRECIGEN, INC. (0001356090) (Issuer)
4 - PRECIGEN, INC. (0001356090) (Issuer)
– Company strengthens focus on building and optimizing commercial readiness and pre-launchactivities for PRGN-2012 in recurrent respiratory papillomatosis –GERMANTOWN, Md., July 23, 2024 /PRNewswire/ -- Precigen, Inc. (NASDAQ:PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced the appointment of Phil Tennant as the Company's chief commercial officer. Mr. Tennant will be responsible for commercial strategy and execution across US and global markets. His initial focus will be on driving commercial readiness activities for the potential launch of the first- and best-in-class PRGN-2012 AdenoVe
JMP Securities analyst Jason Butler reiterates Precigen (NASDAQ:PGEN) with a Market Outperform and maintains $14 price target.
Shares of Science Applications International Corporation (NASDAQ:SAIC) declined 11% to $119.91 following first-quarter results. SAIC reported a 9% revenue decline year over year in the fiscal first quarter of 2025 to $1.847 billion, marginally beating the analyst consensus estimate of $1.844 billion. Adjusted EPS of $1.92 was in line with the analyst consensus estimate, according to data from Benzinga Pro. SAIC shares dipped 11% to $119.91 on Monday. Here are some other stocks moving in today’s mid-day session. Gainers Microbot Medical Inc. (NASDAQ:MBOT) jumped 92.5% to $1.9301 after the company received FDA approval to proceed with its pivotal human clinical trial. Bio-Pa